5 terminated, 4 recruiting, 3 completed, 1 active not recruiting. 5 Phase 2, 4 Phase 1, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 3, Active not recruiting 1, Completed 1 |
| Phase 1 | 4 | Terminated 2, Completed 1, Recruiting 1 |
| Not applicable | 2 | Recruiting 1, Terminated 1 |
Follow Ovarian Adenocarcinoma: new trials by email Literature Review of Ovarian Adenocarcinoma trials Research Report on Ovarian Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fatigue 3 Months After Adjuvant Chemotherapy for Cancer APA program - Breast Cancer, Colorectal Cancer | Not applicable | Recruiting | Centre Antoine Lacassagne | 98 | 2026-09-15 | 2026-09-15 |
| DBC-664 in Adult Patients With Solid Tumors DBC-664 - Malignant Germ Cell Tumor, Lung Adenocarcinoma | Phase 1 | Recruiting | Duboce Biopharmaceuticals, Inc. | 210 | 2026-07-17 | 2026-09-29 |
| Anatomopathological Analysis of the Infundibulopelvic Ligament in Patients With Ovarian Cancer resection of infundibulopelvic ligament - Ovarian Cancer, Ovarian Cancer (OvCa) | Recruiting | Complejo Hospitalario Universitario Insular Materno Infantil | 200 | 2025-07-20 | 2025-08-03 | |
| Clonal Hematopoiesis Chemotherapy and Radiation Effects Study Samples - Lung Cancer (Diagnosis), Osteochondroma | Recruiting | Dana-Farber Cancer Institute | 5000 | 2025-04-04 | 2026-06-30 | |
| A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer TC-510, Fludarabine, Cyclophosphamide - Mesothelioma, Mesotheliomas Pleural | Phase 1 / Phase 2 | Terminated | TCR2 Therapeutics | 14 | 2022-06-21 | 2026-07-13 |
| A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) ELU001 - Ovarian Cancer, Ovarian Neoplasms | Phase 1 / Phase 2 | Terminated | Elucida Oncology | 79 | 2021-09-13 | 2024-08-07 |
| CINSARC Genomic Signature as Predictor of Resectability of Ovarian Adenocarcinoma CINSARC signature - Ovarian Adenocarcinoma | Completed | Institut Claudius Regaud | 150 | 2019-09-15 | 2022-12-23 | |
| The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors Exercise Counseling, Aerobic Exercise, Physiological Support - Ovarian Cancer, Fallopian Tube Adenocarcinoma | Not applicable | Terminated | University of Washington | 64 | 2018-12-05 | 2023-11-29 |
| PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies PDR001, LAG525 - Small Cell Lung Cancer, Gastric Adenocarcinoma | Phase 2 | Completed | Novartis Pharmaceuticals | 76 | 2018-01-24 | 2022-05-27 |
| Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Emactuzumab, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2017-05-05 | 2024-03-13 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
| Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma Cisplatin, Bevacizumab - Ovarian Adenocarcinoma, Fallopian Tube Adenocarcinoma | Phase 1 | Completed | Gustave Roussy, Cancer Campus, Grand Paris | 30 | 2011-06-01 | 2026-08-13 |
| YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Terminated | Gynecologic Oncology Group | 2500 | 2007-09-01 | 2018-05-22 |
Ovarian Neoplasms (6) · Brenner Tumor (3) · Fallopian Tube Neoplasms (3) · Adenocarcinoma Of Esophagus (2) · Breast Neoplasms (2) · Carcinoma, Endometrioid (2) · Carcinoma, Transitional Cell (2) · Cholangiocarcinoma (2) · Colorectal Neoplasms (2) · Pancreatic Neoplasms (2) · Sarcoma (2) · Adenocarcinoma (1) · Adenocarcinoma of Lung (1) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Adenocarcinoma, Mucinous (1)
Neoplasms (11) · Neoplasms by Site (11) · Neoplasms by Histologic Type (9) · Endocrine Gland Neoplasms (8) · Endocrine System Diseases (8) · Adnexal Diseases (7) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Genital Diseases (7) · Genital Diseases, Female (7) · Genital Neoplasms, Female (7) · Gonadal Disorders (7) · Neoplasms, Glandular and Epithelial (7) · Urogenital Diseases (7) · Urogenital Neoplasms (7)
Bevacizumab (2) · CTLA-4 Antigen (1) · Cisplatin (1) · Cyclophosphamide (1) · Disulfides (1) · Exercise (1) · Immunoglobulin G (1) · Ipilimumab (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · Paclitaxel (1) · Practice Guidelines as Topic (1) · Sampling Studies (1) · Specimen Handling (1) · Standard of Care (1)
Centre Antoine Lacassagne (1) · Complejo Hospitalario Universitario Insular Materno Infantil (1) · Dana-Farber Cancer Institute (1) · Duboce Biopharmaceuticals, Inc. (1) · Elucida Oncology (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Gynecologic Oncology Group (1) · Institut Claudius Regaud (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Novartis Pharmaceuticals (1) · TCR2 Therapeutics (1) · University of Washington (1)
United States (9) · France (3) · Guam (1) · Spain (1)
Anil K. Sood, MD (1) · Katherine Bell-McGuinn (1) · Kathryn Pennington (1) · Lachelle D Weeks, MD, PhD (1) · Sandip P Patel (1)
PMID 15047236, PMID 19361838, PMID 26397066, PMID 27246305, PMID 31969335, PMID 33362722, PMID 33882143, PMID 34380663, PMID 34716198, PMID 38243705, PMID 38358334, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40402690, PMID 40588371, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42499790
R21CA215662 (1), U10CA027469 (1), U10CA180868 (1), U10CA180888 (1)